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Abstract
Background: The functional outcome after the treatment of laryngeal cancer is tightly related to the quality of life
of affected patients. The aim of this study is to describe the long-term morbidity and functional outcomes associated
with the different treatment modalities for laryngeal cancer.
Methods: Retrospective chart review of 477 patients undergoing curatively intended treatment for laryngeal cancer at
our tertiary referral center from 2001 to 2014: Details on patient and disease characteristics, diagnostics and treatment
related functional outcomes were analyzed.
Results: With a median follow-up of 51 months, the crude rate of functional larynx preservation was 74.6%.
Radiotherapy +/− chemotherapy was the dominant treatment modality (n = 359–75.3%), whereas 24.7% (n = 118)
underwent primary surgery, with 58.5% (69) receiving adjuvant treatment. The 5-year laryngectomy-free survival was
57% (95% CI, 48–66%) after surgery vs. 69% (95% CI, 64–75%) after chemoradiotherapy (p < 0.01). In stage III-IVB, these
rates were 26% (95% CI, 16–39%) vs. 47% (95% CI, 36–59%), respectively (p < 0.01). Aspiration occurred in 7%,
tracheostomy was necessary in 19.8% and feeding tube placement in 25.4%. Feeding tube and tracheostomy
necessity was higher in the initially surgically treated group. Primary surgery (HR: 1.67, 95% CI: 1.19–2.32; p < 0.01), stage
III-IVB (HR: 4.07, 95% CI: 2.97–5.60; p < 0.01) and tumor recurrence (HR: 3.83, 95% CI: 2.79–5.28; p < 0.01) remained as
adverse factors for laryngectomy-free survival.
Conclusions: Preserving the laryngeal function after cancer treatment is challenging. Advanced tumor stages, primary
surgery and recurrence are related to a poor functional outcome. Therefore, the criteria for initial decision-making
needs to be further refined.
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Background
Squamous cell carcinoma (SCC) of the larynx is a
challenging entity with different treatment strategies
and related functional outcomes. The assessment of
therapy outcome is hindered by the considerable het-
erogeneity of initial disease presentation, as well as
possible debilitating functional impairments related to
the tumor and/or its treatment [1]. Laryngeal func-
tions such as breathing, phonation and swallowing are
crucial to the patients’ quality of life and therefore re-
quire special consideration.
Radiotherapy +/− concomitant chemotherapy ((C)RT)
with organ-preservation protocols have been adopted dur-
ing the last three decades to keep the structural and func-
tional integrity of the larynx intact [2, 3]. Nevertheless, the
damage to healthy tissues through (C)RT is considerable.
Abundant therapy-related toxicity poses substantial prob-
lems [4]. Long-term sequelae of radiation-induced toxicity
include tissue fibrosis, which may lead to a hypo- or im-
mobility of the laryngeal subsites like vocal folds, cricoary-
tenoid joints and aryepiglottic folds. Additional chronic
mucosal swelling, damage to constrictor muscles and po-
tentially occurring chondroradionecrosis may lead to fur-
ther impaired laryngo-pharyngeal function (e.g. airway
obstruction, hoarseness, stenosis and aspiration). These
may lead to an impaired quality of life, especially in loco-
regionally advanced tumor stages [5]. A recent analysis
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identified a high number of feeding tube (FT) and trache-
ostomy dependency in head and neck cancer patients
treated by (C)RT [6]. Therefore, the important question
regarding the outcome after curatively intended treatment
of laryngeal cancer concerns not only the preservation of
the larynx, but also the preservation of its function.
The aim of this study is to report 1) the long-term se-
quelae and functional outcomes at last follow-up; 2)
laryngectomy-free survival; and to 3) identify the factors
associated with poor functional outcome for early- and
advanced-stage laryngeal cancer at our tertiary reference
center.
Methods
The paper and electronic records of all patients pre-
sented with laryngeal SCC at our tertiary referral center’s
head and neck tumor board between 2001 and 2014
were reviewed (n = 594). A total of 117 patients were ex-
cluded due to the following reasons: non-curatively
intended treatment (n = 52), presence of any other syn-
chronous or previous malignant tumor (even if success-
fully treated at the time of laryngeal SCC diagnosis, n =
55), or incomplete documentation (n = 10). Finally, 477
patients with accomplished curatively intended treat-
ment were included in the present study.
Patient and disease characteristics were assessed and
staged with the Union for International Cancer Control
(UICC) 7th edition. The treatment associated immediate,
early and late complications, recurrence patterns, corre-
sponding treatments after recurrence and the functional
long-term outcome at the last follow-up were assessed.
“Functional larynx” was defined as an intact larynx enab-
ling serviceable voice without aspiration, tracheostomy
and/or FT. The dates of death, tumor recurrence and
laryngectomy were available throughout the whole co-
hort. However, it was not possible to fully acquire the
exact time points and durations of all complications: in-
stallation and removal of FTs, opening and closure of
tracheostomies, beginning and end of aspiration etc.
Therefore, these were classified as transient and perman-
ent (i.e. until death or last follow-up) in the database.
Events for laryngectomy-free survival (LFS) were defined
as laryngectomy or death, regardless of the reason (func-
tional, recurrence or upfront within the frame of pri-
mary surgical treatment). The time-to-event outcomes
were calculated based on the date of diagnosis, and eval-
uated by Kaplan-Meier curves and log-rank test. Chi-
square test was used to compare categorical variables. In
order to isolate the adverse factors influencing the func-
tional outcome parameters, multivariate Cox propor-
tional hazard and nominal logistic models with variables
yielding p values < 0.1 via univariate analyses were built,
and backwards elimination was performed. Statistical
analysis was done with JMP software (version 13.0 SAS
Institute, Cary, NC, USA). Statistical significance was set
to a two-tailed alpha of < 0.05. The actuarial rates and
risk estimations are provided with 95% confidence inter-
vals (CI).
Results
A total of 477 patients were eligible for the present study
after curatively intended treatment for laryngeal cancer
in our institution. The median follow-up of surviving pa-
tients was 51months. The patients’ demographic and
disease characteristics are reported in Table 1.
The predominant primary treatment modality was (C)
RT (75.3% - n = 359/477), whereas 24.7% (n = 118/477)
underwent primary surgery. The features and distribu-
tion of treatment modalities are provided in Table 2.
The 5-year overall survival was 79%.
Table 1 Patient and disease characteristics
Parameter n (%)
Total 477 (100%)
Male sex 428 (89.7%)
Median Age (range) 64 (36–92)
Tumor subsite
Supraglottic 124 (26%)
Glottic 281 (58.9%)
Subglottic 13 (2.7%)
Transglottic 59 (12.4%)
cT stage
1a 185 (38.8%)
1b 47 (9.9%)
2 118 (24.7%)
3 79 (16.6%)
4a 47 (9.9%)
4b 1 (0.2%)
cN stage
0 388 (81.3%)
1 24 (5%)
2a 4 (0.8%)
2b 31 (6.5%)
2c 24 (5%)
3 6 (1.3%)
Clinical UICC stage
I 226 (47.4%)
II 97 (20.3%)
III 65 (13.6%)
IVA 82 (17.2%)
IVB 7 (1.5%)
UICC Union for International Cancer Control (7th edition)
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Risk of total laryngectomy
In total, 100 patients (21%) underwent TL. The 5-year
LFS was 57% (95% CI, 48–66%) vs. 69% (95% CI, 64–75%)
with primary surgery vs. primary (C)RT, respectively. Fig-
ure 1a depicts the LFS distributed for UICC stage. When
the stages were grouped as early (I-II) and locally-
advanced (III-IVB), both primary treatment modalities of-
fered similar LFS rates in early stages (Fig. 1b), whereas
non-surgical treatment offered a statistically significant
higher chance to preserve the larynx in locally-advanced
stages (47% (95% CI, 36–59%) vs. 26% (95% CI, 16–39%),
p < 0.01) (Fig. 1c). However, this difference was rather
caused by the number of patients treated with upfront TL
in the surgical group, and not due to salvage or functional
TL after (C)RT (2 patients). In the functional TL group,
the first patient had a cT4a cN1 disease, initially treated
with induction chemotherapy followed by concomitant
(C)RT. She suffered from life-threatening laryngeal sten-
osis and aspiration caused by chondroradionecrosis. The
second patient was diagnosed with a cT1a cN0 glottic la-
ryngeal cancer treated with transoral laser surgery. After
6 years, he underwent salvage (C)RT due to recurrence,
which subsequently caused a chondroradionecrosis lead-
ing to laryngeal stenosis requiring a functional TL.
Risk of tracheostomy
Having tracheostomy at any time point was observed in
53.4% (n = 63/118) and 29.5% (106/359) patients who
were primarily treated with surgery (including TL) and
(C)RT, respectively (p < 0.01). Similarly, the rate of
tracheostomy at the last follow-up was higher in patients
who underwent primary surgical treatment compared to
patients who were initially treated with (C)RT (38.9%
(n = 46/118) vs. 20.9% (n = 75/359), p < 0.01). These dif-
ferences were more prominent in the locally-advanced
tumors: tracheostomy at any time point (87.7% (n = 50/
57) vs. 51.6% (n = 50/97), p < 0.01), tracheostomy at the
last follow-up (70.2% (n = 40/57) vs. 33% (n = 32/97),
p < 0.01). However, when excluding patients who initially
underwent TL, we observed a similar rate for tracheos-
tomy at any time point in surgically treated patients of
29.5% (n = 106/359) and of 30.4% (n = 24/79) in (C)RT
patients (p = 0.881), but a lower rate of tracheostomy at
the last follow-up was observed in surgically treated pa-
tients (8.9% - n = 7/79) than (20.9% - n = 75/359) in (C)
RT patients (p < 0.01).
Risk of feeding tube
Having a FT at any time point was 51.7% (n = 61/118)
and 30.4% (n = 109/359) in primary surgery and (C)RT
groups, respectively (p < 0.01). These ratios were distrib-
uted as 18% (n = 58/323) and 72.7% (n = 112/154) in
stages I-II and III-IVB, respectively (p < 0.01). However,
the rate of being dependent on a permanent FT was
relatively low: 3.4% (n = 4/118) after primary surgery, 5%
(n = 18/359) after primary (C)RT, p = 0.45. Again, after
Table 2 Features and distribution of treatment modalities
Treatment Parameters Primary Treatment Modality
Surgery (Chemo)Radiotherapy
n = 118 (24.7%) n = 359 (75.3%)
Transoral laser microsurgery 62 (52.5%)
Partial open laryngectomy 17 (14.4%)
Total laryngectomy 39 (33.1%)
Neck Dissection 62 (52.5%) 25 (7%)a
Adjuvant treatment 69 (58.5%)
Radiotherapy technique
conventional 2-dimensional 8 (11.6%) 9 (2.5%)
conventional 3-dimensional 47 (68.1%) 230 (64.1%)
static field intensity modulated 10 (14.5%) 48 (13.4%)
volumetric modulated arc 4 (5.8%) 72 (20.1%)
Median total dose in Gy (range) 66 (60–72) 70 (64–76)
Median duration of radiotherapy in days (range) 46 (36–59) 49 (39–71)
Induction chemotherapy 2 (1.7%) 9 (2.5%)
Concomitant systemic therapy 19 (27.5%) 92 (25.6%)
Cisplatin 3w 15 (78.9%) 61 (66.3%)
Carboplatin + 5-fluorouracil 3w 2 (10.5%) 7 (7.6%)
Cetuximab weekly 2 (10.5%) 24 (26.1%)
a up-front neck dissection followed by primary chemoradiotherapy, 3w Three-weekly regimen
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exclusion of patients treated initially with TL, the rate of
a FT at any time point was 29.1% (n = 23/79) in the sur-
gical and 30.4% (n = 109/250) in the (C)RT group (p =
0.826), and the rate of being dependent on a FT at the
last follow-up was 1.3% (n = 1/79) after initial surgery
and 5% (n = 18/359) after initial (C)RT (p = 0.092).
Early and late complications
Two patients died within 30 days of treatment (0.4%).
The following additional rates of complications were
observed: pharyngeal stenosis (4.6% - n = 22/477),
laryngeal stenosis (24.7% - n = 108/438), chondroradio-
necrosis (2.5% - n = 11/438) and soft tissue necrosis
(4.4% - n = 21/477). The rates and corresponding time
intervals of aspiration pneumonias, tracheostomies and
FTs are shown in Table 3.
A functional larynx at last follow-up was obtained in
74.6% (n = 356/477) in the whole cohort, whereas in
84.8% (n = 274/323) and 53.2% (n = 82/154) in early and
locally-advanced stages, respectively (p < 0.01). These
rates were 79.1% (n = 284/359) and 61% (n = 72/118)
with primary (C)RT and surgery, respectively (p < 0.01).
Outcome after salvage treatment
We observed a tumor recurrence in 28.7% (n = 137/477)
of patients. Of those, 99 cases underwent a salvage treat-
ment with curative intent. In this context, 55 TL and 23
tracheostomies were performed. One patient died within
30 days after salvage treatment. The following complica-
tions developed after salvage treatment: permanent FT re-
quirement (35% - n = 35/99), soft tissue necrosis (19% -
n = 19/99), aspiration pneumonia (18% - n = 18/99),
pharyngeal stenosis (15% - n = 15/99), laryngeal stenosis
(8% - n = 8/99) and chondroradionecrosis (2% - n = 2/99).
Multivariate analysis
Locally-advanced tumor stage, primary surgery, and
tumor recurrence remained as adverse factors for per-
manent tracheostomy (Additional file 1: Table S1) and
LFS (Table 4). Tumor subsite as a possibly influencing
variable was not included in the multivariate models, be-
cause the origin of the tumor could not be determined
and was categorized as transglottic in 59 cases (Table 1).
Tumor stage remained as adverse factor for permanent
FT dependency (Additional file 1: Table S1).
Advanced tumor stage (cT), primary surgery and
tumor recurrence were identified as adverse factors re-
garding laryngeal function (as defined above) (summa-
rized in Table 5).
Discussion
In this study, we report long-term functional outcome
after curatively intended laryngeal SCC treatment of all
A
B
C
Fig. 1 Laryngectomy-free survival by stage and primary treatment
modality. Laryngectomy-free survival based on clinical stage (a);
primary treatment modality in early stage (b); primary treatment
modality in locally-advanced stage
Table 3 Time intervals (time of occurrence after end of
treatment) of aspiration pneumonias, tracheostomies and
feeding tubes
Time Intervala Aspirationb
(permanent)
Tracheostomyb
(permanent)
Feeding Tube
(permanent)
Any 7% (1.8%) 19.8% (3.5%) 25.4% (3.5%)
Peri-treatment 3.4% (0.7%) 10% (1.4%) 20.5% (2.5%)
3 to 24 months 2.7% (0.2%) 7.3% (1.6%) 3.6% (0.8%)
After 2 years 0.9% (0.9%) 2.5% (0.5%) 1.3% (0.2%)
a Events after tumor recurrence (73) are censored
b Patients who initially underwent total laryngectomy (n = 39) are excluded
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tumor stages. The 5-year LFS was 57% (95% CI, 48–
66%) vs. 69% (95% CI, 64–75%) with primary surgery vs.
primary (C)RT, respectively (p < 0.01). A functional lar-
ynx was observed in 74.6% of the patients at the time of
last follow-up. Of those, 1.4% remained dependent on
FT. Overall, aspiration was observed in 7% (1.8% per-
manent), tracheostomy in 19.8% (3.5% permanent) and
FT dependency in 25.4% (3.5% permanent) of the whole
cohort within all stages. The multivariate model identi-
fied primary TL, advanced stages and recurrence as ad-
verse effects on LFS.
Laryngeal functions such as the protection of the airway
during breathing and swallowing are crucial for the pa-
tients’ quality of life and are threatened by laryngeal can-
cer and the performed treatments. Total laryngectomy is
separating the airway from the pharynx and esophagus,
and therefore no natural function can be preserved. In
contrast, organ-preservation strategies aim to preserve the
natural anatomy and the function of the larynx, whilst of-
fering similar oncological results. As reported in the
Veterans Affairs trial, which was conducted with a pro-
spective assessment of swallowing and voice, a significant
difference regarding speech intelligibility between the TL
and the (C)RT group after 2 years of follow-up was ob-
served, favoring organ-preservation concerning better
communication. However, no difference regarding swal-
lowing was reported between the two treatment modal-
ities. Surprisingly, no patients were reported using a
percutaneous FT [7, 8]. Our cohort has a high prevalence
of tracheostomy in patients undergoing primary surgical
therapy (53.4%). This is mainly related to cases of primary
TL and prophylactic tracheostomies in cases of partial lar-
yngectomies. Of these patients, 39% ended up with a per-
manent tracheostomy. In the (C)RT group, tracheostomy
was observed in 29%, of which 21% remained permanent
(including salvage TL). Tracheostomy and/or TL was as-
sociated to locally-advanced tumors or salvage treatment
for recurrence. We did not observe other statistically sig-
nificant correlations, probably because we report all tumor
stages and therefore studied a heterogeneous cohort re-
garding tumor extension.
Actually, most of the literature dealing with tracheos-
tomies in the context of laryngeal cancer include also
hypopharyngeal cancers. However, we think that these
tumors should be assessed separately. According to the
literature reporting only results of laryngeal SCC, the ne-
cessity of a tracheostomy varies between 8.2 and 25%
[9–11]. Factors related to permanent tracheostomies are
pre-treatment tracheostomy, extension of disease (poor
laryngeal function prior to treatment), post-irradiated
planned or salvage neck dissection and primary RT in
the context of organ-preservation protocols [12–15].
Moreover, it has been discussed in the literature,
whether the presence of long-term tracheostomy influ-
ences the overall survival, but apparently the 5-year sur-
vival is not influenced [13].
Low aspiration rates of 7% (1.8% permanent) in the
long-term follow-up were assessed in the present study.
Comparing to other studies reporting higher aspiration
rates, we have to consider that they also investigated
asymptomatic patients [16–19]. In contrast, our data
may underestimate the prevalence of subclinical swal-
lowing disorders or aspiration since instrumental swal-
lowing studies were only performed when patients
complained of dysphagia.
In this cohort, a high prevalence of initial FT place-
ment (51.7 and 30.4% in primary surgery and (C)RT
group, respectively) was observed. We explain this high
incidence of enteral feeding at any time point in surgi-
cally treated patients by the short-term enteral nutrition
usually required during wound healing in the immediate
post-operative course. Similarly, the high prevalence of
FT in the primary (C)RT is related to our former policy
to regularly offer prophylactic percutaneous FT place-
ment in loco-regionally advanced tumor stages. In the
long-term outcome, we observed generally a good swal-
lowing function with a low rate of permanent FT de-
pendency (3.4% after primary surgery, 5% after primary
(C)RT). Therefore, the prophylactic percutaneous FT
placement in (C)RT patients appears to be obsolete.
Acute problems with oral feeding related to (C)RT acute
toxicity could be resolved by the placement of a naso-
gastric FT. Regarding Lefebvre et al. (2009), a FT has
been placed in 43 patients and was left in place for more
Table 4 Multivariate model for laryngectomy-free survival
Variable HR (95% CI) p value
Age > 64 vs. ≤64 1.35 (0.99–1.85) 0.060
Female vs. male 0.85 (0.47–1.41) 0.540
Stage III-IV vs. I-II 4.29 (3.11–5.93) < 0.001*
Primary surgery vs. (C)RT 1.84 (1.30–2.57) < 0.001*
Tumor recurrence vs. not 3.83 (2.79–5.28) < 0.001*
CI Confidence interval, (C)RT (Chemo)radiation, HR Hazard ratio
* Remained p < 0.05 after backwards elimination
Table 5 Multivariate model for non-functional larynx at the
time of last follow-up
Variable OR (95% CI) p value
Age > 64 vs. ≤64 0.90 (0.54–1.50) 0.688
Female vs. male 0.83 (0.35–1.98) 0.669
cT 3–4 vs. 1–2 10.19 (5.54–18.73) < 0.001*
cN 2–3 vs. 0–1 0.54 (0.27–1.10) 0.092
Primary surgery vs. (C)RT 2.45 (1.42–4.22) 0.001*
Tumor recurrence vs. not 11.16 (6.36–19.58) < 0.001*
CI Confidence interval, (C)RT (Chemo)radiation, OR Odds ratio
* Remained p < 0.05 after backwards elimination
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than 3 months in 40 patients in the sequential arm
(18%) of the EORTC 24954 trial. Similarly, a FT was
placed in 39 patients and left in place for more than 3
months in 35 patients in the alternating arm (15%) [9].
Wopken et al. (2018) reported in a systematic review of
the literature a high variability of FT dependency over
time. Essentially, after 2 years, the rate varied from 3.7 to
10% [20]. Regarding partial laryngectomies, a recent sys-
tematic review of the literature regarding dysphagia fol-
lowing supracricoid laryngectomy, reported a complete
FT dependency in 0.7% [21]. Weinstein et al. (2007) ob-
served in a cohort of primary and salvage supracricoid
laryngectomies a good swallowing function with only 6%
of the patients requiring a FT [22].
The latest American Society of Clinical Oncology con-
sensus guidelines recommend for T1 and T2 laryngeal
carcinomas either transoral resection or RT alone,
whereas for “early” T3 and T4, either organ-preservation
surgery or RT or (C)RT [23]. However, for extensive T3,
large T4a destructing the cartilages of larynx or poor
pretreatment laryngeal function, TL is advised [23]. Our
results showing a statistically significant adverse func-
tional outcome after the treatment of advanced tumors
support these recommendations. The primary surgical
treatment with consecutive separation of the airway
from the upper digestive tract may resolve many issues
related to a poorly functioning larynx, especially aspir-
ation and swallowing deficits. On the other side, the
functional outcome regarding upfront TL is significantly
inferior according to our results. Therefore, indications
for an initial surgical approach have to be carefully eval-
uated. However, we have to bear in mind that salvage
surgery after (C)RT failure is prone to frequent local and
systemic complications of up to 63% [24–27].
The main limitation of this study is obviously its retro-
spective design. Therefore, we were not able to quantita-
tively report graded long-term toxicity data. Moreover,
the assessment of speech, social and emotional out-
comes was not possible from the documentations. An-
other shortcoming was the lack of exact end dates of all
complications. Finally yet importantly, our cohort is sub-
ject to selection bias due to its retrospective nature. First
of all, there is a clear imbalance between the numbers of
patients treated with primary (C)RT and surgery. A con-
cerning rate of the surgically treated patients with early
stage disease underwent adjuvant RT instead of re-
resection. This may be explained by our previous institu-
tional policy apparently favoring RT over surgery in early
stage larynx cancer, not only as the first treatment op-
tion but also in case of close and positive resection mar-
gins, which underwent a major change few years ago.
An interesting aspect not often taken into consider-
ation in the scientific debate on optimal treatment op-
tions is the patient’s will. It is the duty of the treating
multidisciplinary team to evaluate and offer the best
treatment option(s) to the patients. Functional results
and their impact on the patient’s quality of life play an
important role in counseling the patient. This aspect is a
strength of the present study, reporting the long-term
“real-life” situation in a tertiary referral center. It is our
philosophy to offer the patient different treatment op-
tions, including our opinion about the best treatment.
Finally, the patient should be able to make the informed
decision and have the possibility to trade off chance of
survival against treatment related morbidity and adverse
effects. There are not many studies [28, 29] describing
and analyzing the patient’s will in relation to laryngeal
cancer treatment. Hence, this is an interesting subject,
since laryngeal cancer may be treated in different ways.
The most recent study by Laccourreye et al. (2014) sug-
gest that: (i) laryngeal preservation is not a primary ob-
jective shared by all subjects; (ii) the percentage chance
of cure that subjects would be willing to trade off to
avoid total laryngectomy is extremely variable and (iii)
the information on the major functional risks inherent
to laryngeal preservation protocols has a major impact
on the subject’s treatment decision [30]. Therefore, we
have to encourage the scientific community to continu-
ously monitor and compare functional treatment out-
comes. It is the duty of the multidisciplinary team in a
comprehensive head and neck cancer center not only to
offer best therapy options, but also to adequately counsel
patients on different treatment strategies and related
sequelae.
Conclusions
In this study with a fair median follow-up time, a full con-
servation of laryngeal function at the last follow-up in
74.6% of patients undergoing curatively intended treat-
ment for laryngeal SCC of all stages is reported. Advanced
tumor stages, primary surgery and recurrent disease are
related to a poor functional outcome. Preserving the la-
ryngeal function in laryngeal cancer treatment is challen-
ging. The criteria for initial decision-making needs to be
refined.
Additional file
Additional file 1: Table S1. Multivariate model for permanent
tracheostomy and feeding tube dependency. (DOCX 13 kb)
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